Literatur
- 1
Deutsche AIDS-Gesellschaft (DAIG). Osterreichische AIDS-Gesellschaft (OAG) .
German-Austrian guidelines for antiretroviral therapy in HIV infection. June 1999.
Eur J Med Res.
2000;
5
129-138
- 2
Ammassari A, Murri R, Pezzotti P. et al .
Self-reported symptoms and medication side effects influence adherence to highly
active antiretroviral therapy in persons with HIV infection.
Journal of Acquired Immune Deficiency Syndromes.
2001;
28
445-449
- 3
Anastasi J K, Capili B.
HIV and diarrhea in the era of HAART: 1998 New York State hospitalizations.
American Journal of Infection Control.
2000;
28
262-266
- 4
Barbour J D, Wrin T, Grant R M. et al .
Evolution of phenotypic drug susceptibility and viral replication capacity during
long-term virologic failure of protease inhibitor therapy in human immunodeficiency
virus-infected adults.
J Virol.
2002;
76
11104-11112
- 5
Bassetti S, Battegay M, Furrer H. et al .
Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued?
Swiss HIV Cohort Study.
J Acquir Immune Defic Syndr Hum Retrovirol.
1999;
21
114-119
- 6
Bernasconi E, Boubaker K, Junghans C. et al .
Abnormalities of Body Fat Distribution in HIV-Infected Persons Treated With Antiretroviral
Drugs: The Swiss HIV Cohort Study.
J Acquir Immune Defic Syndr.
2002;
31
50-55
- 7
Brinkman K, Kakuda T N.
Mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors: a
looming obstacle for long-term antiretroviral therapy?.
Curr Opin Infect Dis.
2000;
13
5-11
- 8
Carr A, Miller J, Law M, Cooper D A.
A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with
HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy
syndrome.
AIDS.
2000;
14
F25-F32
- 9
Carr A, Workman C, Smith D E. et al .
Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a
randomized trial.
JAMA.
2002;
288
207-215
- 10
Ciesla J A, Roberts J E.
Meta-Analysis of the relationsip between HIV Infection and risk for Depressive Disorders.
American Journal of Psychiatry.
2001;
158
725-730
- 11
DeSimone J A, Pomerantz R J, Babinchak T J.
Inflammatory Reactions in HIV-1-Infected Persons after Initiation of Highly Active
Antiretroviral Therapy.
Ann Intern Med.
2000;
133
447-454
- 12
Dieterich D T.
Treatment of hepatitis C and anemia in human immunodeficiency virus-infected patients.
J Infect Dis.
2002;
185
S128-S137
(Suppl 2)
- 13
Duran S, Spire B, Raffi F. et al .
Self-reported symptoms after initiation of a protease inhibitor in HIV-infected patients
and their impact on adherence to HAART.
HIV Clinical Trials.
2001;
2
38-45
- 14
Egger M, Hirschel B, Francioli P. et al .
Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland:
prospective multicentre study.
BMJ.
1997;
315
1194-1199
- 15
Egger M, May M, Chene G. et al .
Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy:
a collaborative analysis of prospective studies.
Lancet.
2002;
360
119-129
- 16
Flepp M, Schiffer V, Weber R, Hirschel B.
Modern anti-HIV therapy.
Swiss Med Wkly.
2001;
131
207-213
- 17
Fogarty L, Roter D, Larson S, Gillespie J, Levy R.
Patients adherence to HIV-medication regimens: A review of published and abstract
reports.
Patient Education and Counceling.
2002;
46
93-108
- 18
Furrer H, Egger M, Opravil M. et al .
Discontinuation of Primary Prophylaxis against Pneumocystis carinii Pneumonia in
HIV-1 Infected Adults Treated with Combination Antiretroviral Therapy.
N Engl J Med.
1999;
340
1301-1306
- 19
Furrer H. The Swiss HIV Cohort Study .
Management of Opportunistic Infection Prophylaxis in the Highly Active Antiretroviral
Therapy Era.
Curr Infect Dis Rep.
2002;
4
161-174
- 20
Gordillo V, Del Amo J, Soriano V, Gonzalez-Lahoz J.
Sociodemographic and psychological variables influencing adherence to antiretroviral
therapy.
AIDS.
1999;
13
1763-1769
- 21
Greub G, Ledergerber B, Battegay M. et al .
Clinical progression, survival, and immune recovery during antiretroviral therapy
in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study.
Lancet.
2000;
356
1800-1805
- 22
Hirschel B.
Planned interruptions of anti-HIV treatment.
Lancet Infect Dis.
2001;
1
53-59
- 23
John L, Marra F, Ensom M H.
Role of therapeutic drug monitoring for protease inhibitors.
Ann Pharmacother.
2001;
35
745-754
- 24
Justice AC, Rabeneck L, Hays R D, Wu A W, Bozzette S A. Outcomes Committee of the
AIDS Clinical Trials Group .
Sensitivity, specificity, reliability, and clinical validity of provider-reported
symptoms: a comparison with self-reported symptoms.
Journal of Acquired Immune Deficiency Syndromes.
1999;
21
126-133
- 25
Kahn J O, Walker B D.
Acute human immunodeficiency virus type 1 infection.
N Engl J Med.
1998;
339
33-39
- 26
Kaplan J E, Masur H, Holmes K K.
Guidelines for preventing opportunistic infections among HIV-infected persons - 2002.
Recommendations of the US Public Health Service and the Infectious Diseases Society
of America.
MMWR Recomm Rep.
2002;
51
1-52
- 27
Kaufmann D, Pantaleo G, Sudre P, Telenti A. for the Swiss HIV Cohort Study .
CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active
antiretroviral therapy (HAART).
Lancet.
1998;
351
723-724
- 28
Kirk O, Reiss P, Uberti-Foppa C. et al .
Safe Interruption of Maintenance Therapy against Previous Infection with Four Common
HIV-Associated Opportunistic Pathogens during Potent Antiretroviral Therapy.
Ann Intern Med.
2002;
137
239-250
- 29
Kovacs J A, Masur H.
Drug Therapy: Prophylaxis against Opportunistic Infections in Patients with Human
Immunodeficiency Virus Infection.
N Engl J Med.
2000;
342
1416-1429
- 30
Ledergerber B, Egger M, Erard V. et al .
AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral
therapy: the Swiss HIV Cohort Study.
JAMA.
1999;
282
2220-2226
- 31
Ledergerber B, Egger M, Opravil M. et al .
Clinical progression and virological failure on highly active antiretroviral therapy
in HIV-1 patients: a prospective cohort study.
Lancet.
1999;
353
863-868
- 32
Ledergerber B, Mocroft A, Reiss P. et al. Eight European Study Groups .
Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in
patients with HIV infection who have a response to antiretroviral therapy.
N Engl J Med.
2001;
344
168-174
- 33
Lucas G M, Cheever L W, Chaisson R E, Moore R D.
Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection.
J Acquir Immune Defic Syndr.
2001;
27
251-259
- 34
Marzolini C, Telenti A, Decosterd L A, Greub G, Biollaz J, Buclin T.
Efavirenz plasma levels can predict treatment failure and central nervous system
side effects in HIV-1-infected patients.
AIDS.
2001;
15
71-75
- 35
Mellors J W, Munoz A, Giorg J V. et al .
Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection.
Ann Intern Med.
1997;
126
946-954
- 36
Moore R D, Chaisson R E.
Natural history of opportunistic disease in an HIV-infected urban clinical cohort.
Ann Intern Med.
1996;
124
633-642
- 37
Negredo E, Cruz L, Paredes R. et al .
Virological, immunological, and clinical impact of switching from protease inhibitors
to nevirapine or to efavirenz in patients with human immunodeficiency virus infection
and long-lasting viral suppression.
Clin Infect Dis.
2002;
34
504-510
- 38
Opravil M, Hirschel B, Lazzarin A. et al .
A randomized trial of simplified maintenance therapy with abacavir, Lamivudine, and
Zidovudine in human immunodeficiency virus infection.
J Infect Dis.
2002;
185
1251-1260
- 39
Palella F J, Delaney K M, Moorman A C. et al .
Declining morbidity and mortality among patients with advanced human immunodeficiency
virus infection.
N Engl J Med.
1998;
338
853-860
- 40
Paterson D L, Swindells S, Mohr J. et al .
Adherence to protease inhibitor therapy and outcomes in patients with HIV infection.
Ann Intern Med.
2000;
133
21-30
- 41
Piscitelli S C.
The Role of Therapeutic Drug Monitoring in the Management of HIV-infected Patients.
Curr Infect Dis Rep.
2002;
4
353-358
- 42
Rossi M, Flepp M, Telenti A. et al .
Disseminated M. avium complex infection in the Swiss HIV Cohort Study: declining
incidence, improved prognosis and discontinuation of maintenance therapy.
Swiss Med Wkly.
2001;
131
471-477
- 43
Serovich J M, Kimberly J A, Mosack K E, Lewis T L.
The role of family and friend social support in reducing emotional distress among
HIV-positive women.
Aids Care.
2001;
13
335-341
- 44
Shafer R W.
Genotypic testing for human immunodeficiency virus type 1 drug resistance.
Clin Microbiol Rev.
2002;
15
247-277
- 45
Soriano V, Sulkowski M, Bergin C. et al .
Care of patients with chronic hepatitis C and HIV co-infection: recommendations from
the HIV-HCV International Panel.
AIDS.
2002;
16
813-828
- 46
Spirig R.
In invisibility and isolation: the experience of HIV-affected families in German-speaking
Switzerland.
Qual Health Res.
2002;
12
1323-1337
- 47
Sudre P, Rickenbach M, Taffé P. et al .
Clinical epidemiology and research on HIV infection in Switzerland: the Swiss HIV
Cohort Study 1988 - 2000.
Schweiz Med Wochenschr.
2000;
130
1493-1500
- 48
van Rossum A M, Fraaij P L, de Groot R.
Efficacy of highly active antiretroviral therapy in HIV-1 infected children.
Lancet Infect Dis.
2002;
2
93-102
- 49
Vandamme A M, Houyez F, Banhegyi D. et al .
Laboratory guidelines for the practical use of HIV drug resistance tests in patient
follow-up.
Antivir Ther.
2001;
6
21-39
- 50
Watts D H.
Management of human immunodeficiency virus infection in pregnancy.
N Engl J Med.
2002;
346
1879-1891
- 51
Yeni P G, Hammer S M, Carpenter C C. et al .
Antiretroviral treatment for adult HIV infection in 2002: updated recommendations
of the International AIDS Society-USA Panel.
JAMA.
2002;
288
222-235
- 52
Zinkernagel Ch, Taffe P, Rickenbach M. et al .
Importance of Mental Health Assessment in HIV-Infected Outpatients.
Journal of Acquired Immune Deficiency Syndromes.
2001;
28
240-249
- 53
Zylberberg H, Pol S.
Reciprocal interactions between human immunodeficiency virus and hepatitis C virus
infections.
Clin Infect Dis.
1996;
23
1117-1125
1 Diese Arbeit wurde durch den Schweizerischen Nationalfonds (Grant 3345-062041) unterstützt
Priv.-Doz. Dr. med. Hansjakob Furrer
Ambulatorium für Infektionskrankheiten
Inselspital PKT2B
CH-3010 Bern
Phone: +41/31/6322745
Email: Hansjakob.furrer@insel.ch
